Inclusion Criteria:

- Age > 65

- Comorbidities score, PS and frailty score according to table 1

- No dementia, faecal or urinary incontinence, repeated falls

- ADL = 0, IADL = 0-1

- Life expectancy at least 12 weeks

- Creatinin clearance > = 30 ml/mn (according to Cockcrofts-Gault formula)

- Competency to give written informed consent

- Haematological functions as follows : neutrophiles count > 1.5 x 109/l and platelets
> 100 x 109/l hemoglobin > 9,5 g/dl - Hepatic function as follows : Bilirubin < 1,25
LNS ASAT / ALAT <5 x NAlcPh <5 x N

- PS < 3

- cerebral metastasis eligible if asymptomatic

- Histologically or cytologically confirmed NSCLC

- Stage IV/IIIB4 (T4 with pleural effusion)

- No prior chemotherapy

- relapses of previous NSCLC treated by surgery or radiotherapy are eligible, if the
target is measurable out of initial radiotherapy field and if cytological or
histological proof

- At least one measurable target lesion by RECIST guidelines

Exclusion Criteria:

- symptomatic cerebral metastasis

- Any severe comorbidity calculated by Charlson score according to table 1

- ADL > 0 and IADL > 1- performance status >2 (ECOG)

- peripheral neuropathy grade 2 or more

- dementia, repeated falls, urinary or faecal incontinence

- contra-indication to corticosteroids

- contra indication to a product of this study

- unwilling or unable to comply with study requirements, for personal, family,
sociologic, geographic or any other reason

- inability of the subject to give written informed consent

- lack of liberty following legal or administrative decision

- hypersensitivity to polysorbate

- hypersensitivity to erlotinib or any excipients of this product

- unusual hereditary disorders, as galactosemia, deficit in lactase and syndrome of
malabsorption in glucose or galactose

- participation in concomitant clinical trial

- bronchioloalveolar or neuroendocrine or composite carcinoma

- superior vena cava syndrome